Hans Schreiber

Title: The Innovative Contributions of Hans Schreiber

Introduction

Hans Schreiber is a prominent inventor based in Chicago, IL (US). He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Schreiber's work focuses on developing advanced therapeutic methods for cancer patients.

Latest Patents

Schreiber's latest patents include groundbreaking advancements in cancer treatment. One of his patents is titled "Cancer treatment with 237 CAR-T cell based therapeutics recognizing the Tn epitope." This patent provides Tn epitope-specific chimeric antigen receptors and scFvs, including soluble scFvs and multimeric scFvs. It also outlines methods for identifying cancer subjects and sub-populations that are amenable to anti-Tn immunotherapy, as well as methods for treating cancer. Another notable patent is "Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants." This patent discloses binding proteins that specifically bind to cancer-specific glycosylation variants of proteins, along with methods for making and using these polypeptides to treat, prevent, or ameliorate cancer symptoms.

Career Highlights

Throughout his career, Hans Schreiber has worked with esteemed institutions such as the University of Chicago and the University of Illinois. His research has significantly impacted the field of immunotherapy, particularly in developing targeted treatments for cancer.

Collaborations

Some of Schreiber's notable coworkers include Christian Idel and Boris Engels. Their collaborative efforts have contributed to the advancement of cancer treatment methodologies.

Conclusion

Hans Schreiber's innovative work in cancer treatment exemplifies the importance of research and development in the medical field. His patents reflect a commitment to improving patient outcomes through advanced therapeutic techniques.